- Home
- GH
as 07-08-2024 4:00pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 3.6B | IPO Year: | 2018 |
| Target Price: | $36.83 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.81 - $41.06 | Next Earning Date: | 08-01-2024 |
| Revenue: | $603,725,000 | Revenue Growth: | 25.21% |
| Revenue Growth (this year): | 24.44% | Revenue Growth (next year): | 19.44% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Joyce Meghan V. | GH | Director | Jun 4 '24 | Sell | $27.87 | 100 | $2,787.00 | 4,621 | SEC Form 4 |
| Kalia Kumud | GH | Chief Information Officer | Mar 18 '24 | Buy | $17.82 | 2,187 | $38,962.72 | 12,722 | SEC Form 4 |
| Joyce Meghan V. | GH | Director | Mar 4 '24 | Sell | $19.05 | 100 | $1,905.00 | 4,521 | SEC Form 4 |
| Kalia Kumud | GH | Chief Information Officer | Dec 1 '23 | Sell | $26.37 | 5,800 | $152,954.12 | 5,926 | SEC Form 4 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
Baillie Gifford Reduces Stake in Guardant Health Inc.
MT Newswires
10 days ago
Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36
Zacks
12 days ago
Guardant Health (GH) Just Overtook the 20-Day Moving Average
Zacks
13 days ago
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Simply Wall St.
a month ago
Even after rising 7.4% this past week, Guardant Health (NASDAQ:GH) shareholders are still down 74% over the past three years
MT Newswires
a month ago
Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating
Business Wire
a month ago
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Business Wire
a month ago
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.